Hypha Labs (FUNI)
OTHER OTC:FUNI
Top Page
Hypha Labs
(OTC:FUNI)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.03
▼(-20.00% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily held down by very weak financial performance (zero revenue, sizable losses, negative equity, and continued cash burn). Technical indicators also lean bearish (negative MACD, RSI in the mid-30s, and price below short-term moving averages). Valuation provides little support given the negative P/E and lack of dividend yield.
Positive Factors
Improving cash-flow trend
TTM free cash flow remains negative but shows improvement versus the prior year, indicating management has reduced burn. That trend, if sustained, lowers near-term refinancing pressure and extends runway, offering a more durable path to stability while revenue remains absent.
Negative Factors
Zero revenue run-rate
No reported revenue in the trailing period indicates the company lacks recurring sales or commercial traction. Absent material product commercialization, the firm cannot organically fund operations, making sustained external financing or a strategic pivot necessary for long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash-flow trend
TTM free cash flow remains negative but shows improvement versus the prior year, indicating management has reduced burn. That trend, if sustained, lowers near-term refinancing pressure and extends runway, offering a more durable path to stability while revenue remains absent.
Read all positive factors
Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.32M
Dividend YieldN/A
Average Volume (3M)115.83K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding162,521,820
10 Day Avg. Volume142,592
30 Day Avg. Volume115,825
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.47
Price to Sales (P/S)0.00
P/FCF Ratio-7.46
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hypha Labs Business Overview & Revenue Model
Company Description
Hypha Labs, Inc., engages in the research, development, and commercialization of a bioreactor in the United States. It offers Hypha Micropearl bioreactor, a home appliance designed to accelerate the production of beneficial mushrooms for human con...
How the Company Makes Money
null...
Hypha Labs Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.70M | 2.50M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 1.07M | 715.16K |
| EBITDA | -2.10M | -2.95M | -1.37M | -58.24K | -1.73M | -249.00K |
| Net Income | -2.28M | -3.10M | -785.00K | 246.77K | -2.06M | -687.00K |
Balance Sheet | ||||||
| Total Assets | 391.60K | 409.22K | 493.81K | 1.41M | 1.34M | 1.89M |
| Cash, Cash Equivalents and Short-Term Investments | 42.85K | 38.12K | 91.17K | 271.01K | 56.17K | 295.93K |
| Total Debt | 1.75M | 1.65M | 1.14M | 2.29M | 2.35M | 2.79M |
| Total Liabilities | 2.74M | 2.51M | 1.42M | 3.28M | 4.08M | 2.94M |
| Stockholders Equity | -2.35M | -2.10M | -926.69K | -1.87M | -2.41M | -1.05M |
Cash Flow | ||||||
| Free Cash Flow | -553.50K | -412.94K | -1.42M | 112.53K | -202.51K | -192.17K |
| Operating Cash Flow | -522.27K | -379.98K | -1.39M | 112.53K | -184.79K | -135.97K |
| Investing Cash Flow | -31.24K | -32.97K | 2.15M | 263.33K | -660.37K | -286.21K |
| Financing Cash Flow | 559.78K | 359.89K | -1.28M | -161.02K | 605.39K | 635.36K |
Hypha Labs Risk Analysis
Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We plan to increase the amount of authorized shares of our common stock and our preferred stock. Q3, 2024
2.
We have outstanding shares of Series C Preferred stock held by our sole executive officer that will enable him to control a majority of the total voting power of the Company. Q3, 2024
3.
Our limited operating history in our current business makes it difficult to evaluate our current business and future prospects and the risk of your investment. Q3, 2024
Hypha Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $33.86M | -3.95 | -61.62% | ― | 4455.07% | 77.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.93M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $46.33M | -1.54 | 1237.14% | ― | -74.73% | 95.81% | |
42 Neutral | $3.70M | -0.10 | -262.78% | ― | ― | 79.45% | |
41 Neutral | $3.32M | -2.91 | 119.09% | ― | ― | ― |
* Healthcare Sector Average
FUNI
Hypha Labs
0.02
>-0.01
-33.33%
NBY
NovaBay Pharma
1.74
0.09
5.33%
AEMD
Aethlon Medical
2.23
-26.01
-92.10%
ENVB
Enveric Biosciences
1.96
-12.56
-86.50%
EVAX
Evaxion Biotech
4.06
2.73
205.26%
SPRC
SciSparc Ltd.
3.42
-48.65
-93.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.